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E. Miklaševičs*
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Low-penetrance gene variants and their combinations are topical study objects in breast cancer pathogenesis. Single nucleotide 
polymorphism rs61764370, localized in 3 UTR of KRAS gene, plays an important role in the development and progression of seve-
ral cancers. The aim of our study was to determine the KRAS variant impact on breast cancer morbidity. Patients and Methods: 
2214 patients diagnosed with breast cancer and 861 healthy controls were screened for KRAS variant by RFLP method. Available 
clinical data were collected and processed using statistical analysis methods. Results of present study suggest the KRAS variant 
impact on breast cancer development risk in premenopausal women, but it has no effect on breast cancer prognosis. We did not 
observe any KRAS variant effect on breast cancer patient 10-year disease-specific survival rates.
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S i n g l e  n u c l e o t i d e  p o l y m o r p h i s m 
rs61764370 (GRCh38 38.1/141) localized in 3 UTR 
of the KRAS gene (MIM 190070) alters complemen-
tary site of KRAS inhibitory micro-ribonucleic acid 
let-7, thus hinders let-7-mediated regulation of the 
gene [1, 2]. The results of in vitro studies describing 
the impact of the KRAS variant on cell processes are 
contradictory, setting two potential scenarios: over-
expressed KRAS gene [1] or lower let-7 levels [3]. 
There are conflicting data about the KRAS variant ef-
fect on breast cancer biology [2, 4]. In a recent study 
from Ovarian Cancer Association Consortium and 
colleagues with performed rs61764370 genotyping for 
140,012 women the authors reported no association 
of rs61764370 with risk of ovarian or breast cancer 
nor with clinical outcome [5]. Whereas McVeigh and 
colleagues described the KRAS variant as significant 
marker, which in combination with estrogen withdrawal 
increases breast cancer risk and predicts aggressive 
tumor biology [6].
MATERIALS AND METHODS
Study groups. The breast cancer patient group 
consisted of 2214 European descent women aged 
24 to 95 years (mean age 60.35 ± 12.59 years), who 
have been diagnosed with breast cancer  according 
to ICD-10. Patients with proven founder variants 
c.181T>G (p.Cys61Gly), c.4035delA (p.Glu1346Lysfs) 
and c.5266dupC (p.Gln1756Profs) of the BRCA1 gene 
(MIM 113705) and/or positive family history of disease, 
indicating a possible presence of high penetrance vari-
ant, were excluded from the study group.
861 European descent voluntary women aged 
18 to 92 years (mean age 47.63 ± 19.07 years) without 
any oncologic illnesses reported at the time of appli-
cation were included in the control group. The distri-
bution of cases and controls by age groups is shown 
in Table 1.
Table 1. Frequency of KRAS variant carriers among breast cancer pa-
tients and healthy women stratified by age
Age group
Breast cancer patients Healthy women
Number 
of patients, 
n (%)
Frequency 
of KRAS mu-
tation, n (%)
Number 
of patients, 
n (%)
Frequency 
of KRAS mu-
tation, n (%)
≤ 40 years 128 (5.8) 17 (13.3) 358 (41.7) 32 (8.9)
41–60 years 966 (43.6) 111 (11.5) 263 (30.5) 14 (5.3)
61–80 years 1015 (45.9) 122 (12.0) 194 (22.5) 22 (11.3)
> 80 years 105 (4.7) 16 (15.2) 46 (5.3) 4 (8.7)
Informed consent was obtained from all individual 
participants included in the study.
Genotyping of rs61764370. Genomic DNA was 
isolated from peripheral blood leukocytes using Flexi-
Gene DNA Kit (Qiagen, Hilden, Germany). The presence 
of rs61764370 was detected by restriction fragment 
length polymorphism analysis. PCR was performed 
as described elsewhere [1]. Primer sequences 
used for PCR were as follows: forward — 5-CCT-
GAGTAGCTGGGATTACA-3 reverse — 5-GGATAC-
CATATACCCAGTGCCTT-3. Touch-down PCR was 
performed in following conditions: 96 °C for 10 min 
as initial denaturation, followed by 20 cycles of 96 °C for 
30 s, 63 °C for 30 s and 72 °C for 45 s, reducing primer 
hybridization temperature — 0.5 °C per cycle, prolonged 
with 20 cycles of 96 °C for 30 s, 53 °C for 30 s and 
72 °C for 45 s, with final elongation at 72 °C for 10 min. 
Amplification products were digested by restriction 
endonuclease HinfI (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) and separated by 2% agarose 
gel electrophoresis.
Statistical analysis was performed with program 
R version 3.1.0., statistical significance was set at 95% 
level. The odds ratio was calculated by using “cc” func-
tion of Epicalc package. Chi square test was performed 
by using “chisq.test” function of Stat package for 
analysis of the distribution of KRAS variant in patients 
with various subtypes of breast cancer.
Ethical approval. All procedures performed 
in studies involving human participants were in ac-
cordance with the ethical standards of the institutional 
committee and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. 
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by the Ethical Committee of Riga Stradins University.
RESULTS
The KRAS variant was detected in 12.01% 
(266/2214) breast cancer cases and 8.36% (72/861) 
controls. Prevalence of rs61764370 variant among 
control subjects was similar to one in Europe — 
7.6% [1].There was no statistically significant diffe-
rence between the cancer stages (χ2 test = 5.43, df = 3, 
p = 0.14) and the mean age at the moment of diagnosis 
of the KRAS variant positive (60.72 years) and negative 
(60.31 years) breast cancer patients.
The higher likelihood of being the KRAS variant 
carrier for breast cancer patients compared to healthy 
women was found (case-control study, odds ratio 
(OR) = 1.50; 95% confidence interval (CI) = 1.13–2.0, 
p = 0.004, statistical power = 85.09%). The same 
cohe rence was examined stratifying patients into dif-
ferent age groups. Although the frequency of KRAS 
variant in cases and controls divided by age groups 
is variable (Fig. 1), only women diagnosed with breast 
cancer at the age of 41–60 years demonstrate a higher 
pro bability of being carriers of the KRAS variant com-
pared to controls at the same age (OR = 2.30; 95% 
CI = 1.28–4.42; p = 0.003). There were no similar as-
sociations found in other age groups (Table 2).
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Fig. 1 Frequency of K RAS variant among cases and controls 
in different age groups
Table 2. Age stratified case-control study results
Age group OR 95% CI p value
≤ 40 years 1.55 0.78–3.01 0.174
41–60 years 2.30 1.28–4.42 0.003
61–80 years 1.06 0.65–1.80 0.904
> 80 years 1.88 0.56–8.21 0.434
The survival data were available for all breast can-
cer patients. Statistical analysis based on these data 
did not reveal any differences in disease-specific sur-
vival rates between KRAS variant positive and negative 
breast cancer patients in 10 year observation period 
(log-rank test, p = 0.695) (Fig. 2).
DISCUSSION
The results of our study suggest that the KRAS 
variant is slightly more frequent among breast cancer 
patients than it is in the healthy control group.
So far it has been reported that the KRAS variant 
significantly increases the risk of ovarian cancer, triple 
negative breast cancer and lung cancer [1, 4, 7]. Recent 
study of McVeigh and colleagues described the KRAS 
variant as significant marker, which in combination with 
estrogen withdrawal increases breast cancer risk and 
predicts aggressive tumor biology [6]. Our study de-
monstrated a slightly increased risk of deve loping breast 
cancer for KRAS variant positive women. After stratifying 
patients into different age groups it is noteworthy that the 
presence of the variant only in 41–60 years of age group 
was associated with increased morbidity. Although the 
data about hormonal levels in investigated patients were 
not obtained, it is tempting to speculate that the KRAS 
variant may be a predisposing factor for breast cancer 
development in association with hormonal fluctuations, 
which is a part of normal physiology for women in this 
age group. This finding of present study is in concert 
with results published by McVeigh and colleagues [6].
Ovarian Cancer Association Consortium and col-
leagues published the results based on large cohort 
study — no association of rs61764370 with risk of ova-
rian or breast cancer nor with clinical outcome [5]. 
Contradictions may be explained by the absence 
of stratification in the age groups.
KRAS variant association with premenopausal 
women in the context of triple negative breast cancer 
has been described before [4, 6]. Our study shows 
an apparent association between KRAS variant and 
breast cancer risk among women at menopausal age, 
suggesting that this sequence variant may be indeed 
a predisposing factor for breast cancer development 
in association with hormonal fluctuations.
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Fig. 2 10-year disease-specific survival rates for KRAS variant 
positive and negative breast cancer patients (Kaplan — Meier 
analysis)
The survival analysis showed no difference in dise-
ase-specific survival rate between the KRAS variant 
positive and negative breast cancer patients du ring 
10 years long observation period (log-rank test, 
p = 0.695). This result indicates that the KRAS variant 
is involved in the breast cancer development in specific 
age group (41–60 years of age) but not in the prognosis.
294 Experimental Oncology 37, 292–294, 2015 (December)
We carried analyses (data not shown) investiga ting 
proportion distribution of breast cancer molecular 
subtypes between KRAS variant positive and nega-
tive patients, as this variant allele has been previously 
associated with HER2-positive and triple negative 
tumors [2, 4, 6]. Our study results showed only a slight 
trend of increasing triple negative breast cancer cases 
among KRAS variant positive breast cancer patients 
and luminal B breast cancer cases among KRAS vari-
ant negative patients, though these data did not reach 
statistical significance.
Presented results imply the necessity for extended 
study of the KRAS variant frequency in combination 
with clinical data among premenopausal women.
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